Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, David KA, Park S, Beaven AW, Habib A, Bachanova V, Nakhoda S, Khan N, Lynch RC, Smith SD, Ho VT, LaCasce A, Armand P, Herrera AF.
Merryman RW, et al. Among authors: joyce rm.
Blood Adv. 2021 Mar 23;5(6):1648-1659. doi: 10.1182/bloodadvances.2020003556.
Blood Adv. 2021.
PMID: 33710337
Free PMC article.